We could not find any results for:
Make sure your spelling is correct or try broadening your search.
– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of a Scientific Advisory Committee from world-renowned...
– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of a Scientific Advisory Committee from world-renowned...
BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology, an LG Chem company (“AVEO”), today announced The Oncologist has published a post-hoc analysis of long-term progression free survival...
Phase 3 Registrational Trial Seeks to Improve Survival Outcomes in Underserved HPV-negative R/M Head and Neck Cancer Patient PopulationTrial Launch Follows FDA Fast Track Designation of...
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology...
Neurocrine Biosciences came within a penny of Tuesday’s all-time high of $125.99 before pulling back. The company’s treatment for a disorder called tardive dyskinesia, which accounts for...
By Stephen Nakrosis Shares of AVEO Pharmaceuticals Inc. touched a 52-week high on Tuesday, following news that LG Chem Ltd. agreed to acquire the company for $15 a share in an all-cash...
By Colin Kellaher Shares of AVEO Pharmaceuticals Inc. jumped nearly 40% in premarket trading Tuesday after the oncology-focused biopharmaceutical company agreed to be acquired by South...
By Kwanwoo Jun South Korea's LG Chem Ltd. has decided to acquire U.S. biotech company AVEO Pharmaceuticals Inc. for $566 million to enter the U.S. cancer treatment market. The acquisition...
By Chris Wack AVEO Oncology Inc. said it has entered into a clinical trial collaboration and supply agreement in North America with Eli Lilly & Co. to evaluate ficlatuzumab in combination...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions